Australia markets closed

Tonix Pharmaceuticals Holding Corp. (TNXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1625-0.0075 (-4.41%)
At close: 04:00PM EDT
0.1668 +0.00 (+2.65%)
After hours: 07:30PM EDT

Tonix Pharmaceuticals Holding Corp.

26 Main Street
Suite 101
Chatham, NJ 07928
United States
862 799 8599
https://www.tonixpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees103

Key executives

NameTitlePayExercisedYear born
Dr. Seth Lederman M.D.Co-Founder, President, CEO & Chairman675kN/A1958
Mr. Bradley Saenger CPACFO & Treasurer640.77kN/A1974
Mrs. Jessica Edgar MorrisChief Operating Officer654.55kN/AN/A
Dr. Gregory M. Sullivan M.D.Chief Medical Officer & Secretary661.44kN/A1966
Dr. Herbert W. Harris M.D., Ph.D.Executive Vice President of Translational MedicineN/AN/AN/A
Dr. Bruce L. Daugherty M.B.A., Ph.D.Executive Vice President of Research300.38kN/A1958
Ms. Siobhan Fogarty B.Sc., M.Sc.Executive Vice President of Product DevelopmentN/AN/AN/A
Dr. Darryl Rideout Ph.D.Executive Vice President of Experimental ChemistryN/AN/AN/A
Dr. Sina Bavari Ph.D.Executive Vice President of Infectious Disease Research & DevelopmentN/AN/AN/A
Dr. Zeil Rosenberg M.D., M.P.H.Executive Vice President of MedicalN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its development portfolio focuses on central nervous system disorders. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Corporate governance

Tonix Pharmaceuticals Holding Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.